{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:31:52Z","timestamp":1792485112568,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2016,1,15]]},"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Vedolizumab is a gut-selective antibody to \u03b1\n                      <jats:sub>4<\/jats:sub>\n                      \u03b2\n                      <jats:sub>7<\/jats:sub>\n                      integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Safety data (May 2009\u2013June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received \u22651 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1\u20131977\u2005days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (\u22640.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor \u03b1 antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p&lt;0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p&lt;0.0001). Investigator-defined infusion-related reactions were reported for \u22645% of patients in each study. Eighteen vedolizumab-exposed patients (&lt;1%) were diagnosed with a malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      NCT01177228,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00619489\">NCT00619489<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00783718\">NCT00783718<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00783692\">NCT00783692<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01224171\">NCT01224171<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00790933\">NCT00790933<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2015-311079","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T18:17:54Z","timestamp":1460571474000},"page":"839-851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":723,"title":["The safety of vedolizumab for ulcerative colitis and Crohn's disease"],"prefix":"10.1136","volume":"66","clinical-trial-number":[{"clinical-trial-number":"nct00619489","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00783718","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00783692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01224171","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00790933","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Katholieke Universiteit and University Hospital Gasthuisberg, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California San Diego and UC San Diego Health System, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D'Haens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Sankoh","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Fox","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asit","family":"Parikh","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Milch","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brihad","family":"Abhyankar","sequence":"additional","affiliation":[{"name":"Takeda Global Research and Development Centre (Europe) Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,2,18]]},"reference":[{"key":"2025090712494827000_66.5.839.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0176-2"},{"key":"2025090712494827000_66.5.839.2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973"},{"key":"2025090712494827000_66.5.839.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-014-0113-2"},{"key":"2025090712494827000_66.5.839.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"2025090712494827000_66.5.839.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"2025090712494827000_66.5.839.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"2025090712494827000_66.5.839.7","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281f538"},{"key":"2025090712494827000_66.5.839.8","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21896"},{"issue":"Suppl 1","key":"2025090712494827000_66.5.839.9","first-page":"A66","article-title":"Long-term efficacy of vedolizumab therapy for ulcerative colitis","volume":"2","author":"Feagan","year":"2014","journal-title":"United Eur Gastroenterol J"},{"issue":"Suppl 1","key":"2025090712494827000_66.5.839.10","first-page":"A66","article-title":"Long-term efficacy of vedolizumab therapy for Crohn's disease","volume":"2","author":"Hanauer","year":"2014","journal-title":"United Eur Gastroenterol J"},{"key":"2025090712494827000_66.5.839.11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"2025090712494827000_66.5.839.12","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"2025090712494827000_66.5.839.13","doi-asserted-by":"crossref","unstructured":"Wyant T , Estevam J , Yang L , et al . Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 2015 doi:10.1002\/cyto.b.21236.","DOI":"10.1002\/cyto.b.21236"},{"issue":"Suppl 1","key":"2025090712494827000_66.5.839.14","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.14309\/00000434-201310001-01673","article-title":"Risk assessment and minimization for progressive multifocal leukoencephalopathy (PML) (RAMP): a program to assess the potential early signs and symptoms of PML during clinical development of vedolizumab","volume":"108","author":"Clifford","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"(Suppl 1)","key":"2025090712494827000_66.5.839.15","first-page":"Abstract p-140","article-title":"Pharmacokinetic\/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2","volume":"19","author":"Rosario","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2025090712494827000_66.5.839.16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju027.740"},{"key":"2025090712494827000_66.5.839.17","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1065242"},{"key":"2025090712494827000_66.5.839.18","unstructured":"World Health Organization (WHO). Global tuberculosis report 2014. Geneva, Switzerland: WHO Press, 2014."},{"issue":"Suppl 1","key":"2025090712494827000_66.5.839.19","first-page":"A82","article-title":"Safety of vedolizumab alone or with concomitant corticosteroids and\/or immunosuppressives in patients with ulcerative colitis or Crohn's disease","volume":"2","author":"Colombel","year":"2014","journal-title":"United Eur Gastroenterol J"},{"key":"2025090712494827000_66.5.839.20","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182a827d2"},{"key":"2025090712494827000_66.5.839.21","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2014.881715"},{"key":"2025090712494827000_66.5.839.22","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.138"},{"key":"2025090712494827000_66.5.839.23","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511435105"},{"key":"2025090712494827000_66.5.839.24","unstructured":"Biogen. Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec Inc., 2013."},{"key":"2025090712494827000_66.5.839.25","unstructured":"Biogen. US-TYSABRI-update. June 2015 ed. MedInfo: Biogen, 2015."},{"key":"2025090712494827000_66.5.839.26","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.218"},{"key":"2025090712494827000_66.5.839.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.006"},{"key":"2025090712494827000_66.5.839.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.03.034"},{"key":"2025090712494827000_66.5.839.29","doi-asserted-by":"crossref","unstructured":"Mulholland MW , Doherty GM . Complications in surgery. Philadelphia: Lippincott Williams & Wilkins, 2006.","DOI":"10.1097\/01.shk.0000245021.08988.da"},{"key":"2025090712494827000_66.5.839.30","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21643"},{"key":"2025090712494827000_66.5.839.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.04871.x"},{"key":"2025090712494827000_66.5.839.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.09.002"},{"key":"2025090712494827000_66.5.839.33","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828075bd"},{"key":"2025090712494827000_66.5.839.34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12385"},{"key":"2025090712494827000_66.5.839.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2009.02.037"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2015-311079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:49:54Z","timestamp":1757274594000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2015-311079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,18]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,4,7]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1136\/gutjnl-2015-311079"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2015-311079","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726158027.793562780","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,18]]}}}